NeoNeuro SAS has entered into a collaboration under the leadership of Professor Harald Hampel to work with the INSIGHT cohort for the application of the Aptamarker Platform to pre-AD samples. The cohort is an innovative study of Alzheimer’s disease, and one of the first in the world to monitor healthy subjects at-risk. NeoNeuro is using this cohort to extend their validation of the Aptamarker platform. Specifically, validation of Alzheimer’s disease to diagnosis amyloid status in healthy elderly subjects.

INSIGHT is made possible through an innovative new scheme in medical research. It is a multi-partner foundation that focuses the Investissements d’Avenir (Investment for the Future) programme via IHU-A-ICM and Pfizer combined with the teams at IM2A and ICM. The shared objective is to provide better understanding of Alzheimer’s disease. INSIGHT is an ancillary study of the MEMENTO national cohort.

For more information on the INSIGHT-preAD study, find the publication on The Lancet Neurology.